Pacira BioSciences Completes Viatris Merger, Revises Notes and Ends Credit Facility

Pacira BioSciences (PCRX) completed its merger with Viatris, revising its $287.5M convertible notes to reflect the $36.50-per-share cash consideration, unwinding capped call transactions, and repaying $96,392.50 to terminate its credit facility with Wells Fargo.

Original reporting
Published Nov 17, 2026, 2:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 2:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pacira BioSciences Completes Viatris Merger, Revises Notes and Ends Credit Facility — source image
Decision brief

The 30-second read

$PCRXNeutralMed
01

Why it matters

Amending conversion terms to match the merger’s $36.50-per-share cash consideration and terminating the credit facility should reduce refinancing risk and simplify the post-merger capital stack.

02

Market read

This is a post-merger financing and hedging unwind that can affect convertible pricing, equity risk, and near-term hedging flows.

03

What to watch

Traders may need to monitor how the amended conversion terms and capped call unwind affect near-term hedging flows and convertible arbitrage positioning, which the article does not quantify.

Relevance 7/10Novelty 7/10Timing: effective Nov 17, 2026, immediately after merger completion

Background

Pacira completed its merger with Viatris and used the closing to restructure related financing instruments.

Company-level read

Ticker impact

$PCRXNeutralMedium confidence
Context

Pacira BioSciences completed its Viatris merger and amended $287.5M convertible notes, unwound capped calls, and repaid/terminated its credit facility.

Expected impact

Likely modest positive bias as the market prices lower leverage and clearer note conversion terms post-merger.

Evidence & confidence

The article discloses multiple balance-sheet actions (note amendment, capped call unwind, credit facility termination) with explicit linkage to the merger consideration, but it does not provide incremental operating guidance or a new deal price change beyond the stated $36.50 cash consideration.

Market effects

Biopharma capital-structure refinancing around M&A can influence sentiment toward other deal-linked issuers and convertible-note liquidity.

Primarily US credit and equity microstructure effects for the issuer’s convertibles and hedging counterparties.

Limited, as the disclosed actions are company-specific and not a cross-market policy or sector-wide shock.

Counterpoint

The actions may be largely mechanical post-merger (conversion term alignment, capped call unwind, credit payoff), so equity impact could be muted versus the market’s prior expectations for the merger.

Key entities

  • Pacira BioSciences

    Issuer that amended convertible notes, unwound capped calls, and repaid/terminated its credit agreement after completing the Viatris merger.

  • Viatris

    Counterparty in the merger whose cash consideration is referenced in the note conversion amendment.

  • Wells Fargo Bank

    Credit agreement counterparty that is repaid and whose facility is terminated.

  • Computershare Trust Company

    Counterparty for the supplemental indenture amending the convertible notes.

Related articles

$VTRSMedAI 8/10

Viatris Inc (VTRS): Completion of Acquisition or Disposition of Assets

Viatris Inc (VTRS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Viatris Completes Acquisition of Pacira BioSciences PITTSBURGH – Nov. 17, 2026 – Viatris Inc. (“Viatris”) (Nasdaq: VTRS), a global healthcare company, today announced that it has completed its acquisition of Pacira BioSciences, Inc. (“Pacira”) (Nasdaq: PCRX), a leade

$PCRXMedAI 9/10

Pacira BioSciences, Inc. (PCRX): Completion of Acquisition or Disposition of Assets

Pacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 November 17, 2026 To: Holders of Pacira BioSciences, Inc. 2.125% Convertible Senior Notes due 2029 (CUSIP: 695127AJ9) and Computershare Trust Company, National Association as Trustee, Paying Agent and Conversion Agent Corporate Trust Office 1505 Energy Park Drive St.

$VTRSMedAI 8/10

Viatris Completes Acquisition of Pacira BioSciences

Viatris Inc. (VTRS) completed its acquisition of Pacira BioSciences (PCRX) for $36.50 per share. The deal, announced in October, aims to strengthen Viatris's U.S. pain management business. Pacira's shares will be delisted from Nasdaq, and Viatris expects the acquisition to add $90M-$100M in revenue for the rest of 2026.

$PCRXLow

Pacira BioSciences, Inc. (PCRX): RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly…

Pacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure. As previously disclosed, pursuant to an agreement entered into between the Research Development Foundation (“RDF”) and a wholly-owned subsidiary of Pacira BioSciences, Inc. (the “Company” or “Pacira”), the Company was required to pay RDF a low